Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4035 - Safety and efficacy of eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients. An Italian multicenter experience

Date

10 Oct 2016

Session

Poster display

Presenters

eufemia Lutrino

Citation

Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365

Authors

E.S. Lutrino1, L. Orlando1, G. Giordano2, C. Zamagni3, C. Caliolo1, A. Febbraro4, M. Giampaglia5, G. Dima6, A. Quaranta1, C. Scavelli7, D. Bilancia5, G. Filippelli6, C. Fontanella8, P. Schiavone1, P. Fedele1, M. Enrica1, D. Rubino3, S. Cinieri1

Author affiliations

  • 1 Medical Oncology, Ospedale A. Perrino, 72100 - Brindisi/IT
  • 2 Oncologia, Ospedale "Sacro Cuore di Gesù" Fatebenefratelli, 82100 - Benevento/IT
  • 3 Oncologia Medica "addarii", Policlinico S. Orsola-Malpighi-"F.Addarii", 40138 - Bologna/IT
  • 4 Medical Oncology, Ospedale "Sacro Cuore di Gesù" Fatebenefratelli, Benevento/IT
  • 5 Oncologia, Azienda ospedaliera Regionale S. Carlo di Potenza, 85100 - Potenza/IT
  • 6 Oncologia, Ospedale S.Francesco, 87027 - Paola/IT
  • 7 Oncologia, Ospedale "Sacro Cuore di Gesù" Fatebenefratelli, 73042 - gallipoli/IT
  • 8 Medical Oncology, AOU Santa Maria della Misericordia, 33100 - Udine/IT
More

Resources

Abstract 4035

Background

Data on the combination of eribulin and trastuzumab (E/T) are limited, although recent analyses demonstrated safety and efficay for its use. The aim of this observational, retrospective, multicenter study was to examine the tolerability and the clinical activity of eribulin plus trastuzumab in the treatment of HER2 positive ABC.

Methods

Patients (pts) treated with eribulin mesylate (1.23 mg/m2 on days 1 and 8 of a 21-day cycle) plus standard dosing of trastuzumab (16 pts received 3-week schedule: 8 mg/kg load, 6 mg/kg q 3 weeks; 8 pts received weekly schedule: 4 mg/kg load, 2 mg/kg q week) in 6 Italian oncology units were include. Data on response rate (RR), overall survival (OS) and safety were reported.

Results

Between October 2012 and November 2015 twenty four pts with HER2-positive ABC were included. Median age was 57 years (32 to 74). All patients were heavily pretreated: the median number of prior chemotherapy (CT) regimens for MBC was 3 (range 2-9). ECOG PS pre-E/T treatment was 0-1 in 75%. The median number of cycles with E/T was 11,5 (range 2-26). Complete response (CR) was achieved in 1 pts (4,2%), 9 pts (37,5%) achieved partial response (PR), 9 pts (37,5%) had stable disease (SD), and 5 pts (20,8%) had progressive disease (PD). Median OS was 7,7 months (range 2,8-30,5). Comorbidities at study entry were cardiovascular (including hypertension), 54.2%; diabetes, 8.3%; other diseases, 16.7%. Neutropenia was the most common clinical grade 3/4 adverse event (25%); one case (4,2%) of febrile neutropenia was observed. Main grade 3/4 non hematological toxicities were fatigue (4,2%), peripheral neuropathy (4,2%) and nausea (4,2%). Alopecia was observed in more than half of pts (66,7%). Dose reduction was applied in 6 pts (25%); three pts (12,5%) interrupted the treatment prematurely.

Conclusions

Tolerability and efficacy of E/T combination schedule are encouraging . The results of this study indicated that this combination might be considered for future prospective study.

Clinical trial identification

Legal entity responsible for the study

Saverio Cinieri

Funding

Medical Oncology Group Ospedale Perrino Brindisi

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings